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L E A R N I N G O B J E C T I V E S
Overview
Tuesday 24 March is the World Health 
Organization’s World Tuberculosis Day. The 
goal is to end the global epidemic by 2035.1
Tuberculosis (TB) is one of the top 10 
causes of death worldwide; one third of 
the world population is believed to be 
affected.2,3 Mycobacterium tuberculosis is 
the most common causative organism. 
Mycobacterium africanum and 
Mycobacterium canetti cause rare cases 
of TB in Africa.3,4 DNA analysis indicates 
that the M. tuberculosis complex emerged 
approximately 70,000 years ago and 
accompanied migration out of Africa, 
expanding as a result of increasing 
population density in the Neolithic 
period.⁵ Between the 17th and 19th 
centuries, TB killed 1 in 5 adults in North 
America and Europe. In the developing 
world today, it is a cause of both high 
morbidity and mortality.5 In the World 
Health Organization’s 2018 Global 
Tuberculosis Report, it was identified as 
‘the leading cause [of death] from a single 
infectious agent.’⁶
Transmission of TB 
TB is an airborne pathogen that 
predominantly affects the lungs.⁴ 
Transmission is mainly by inhalation of 
infectious droplets.⁷ This is usually through 
prolonged sharing of airspace with an 
infected person.⁷ The incubation period 
can vary between 2–10 weeks.3,8 Risk of 
transmission is greatest in the interval 
prior to diagnosis.⁸ Once infected, active 
TB only occurs in 5–10% of those that are 
immunocompetent.8 
Where TB is fully drug-susceptible, 2 
weeks of standard daily treatment may 
render the patient noninfectious.9 
Zoonotic tuberculosis (Mycobacterium 
bovis) from cattle and their food products 
is rare (1.4% of cases overall); the primary 
reservoir is humans.3,10 Mycobacterium 
microti (rodents) and Mycobacterium 
pinnipedii (seals) have also been reported 
to cause zoonotic TB in humans.3 
TB in Australia
TB is uncommon in Australia. Effective 
TB control has resulted in stable and low 
TB incidence rates since 1985. Incidence 
reduction, however, has not been achieved 
even though risk factors (e.g. poverty, poor 
TB practices, political instability and HIV 
disease) found in other parts of the world 
do not contribute to the epidemiology of 
TB in Australia.11
In Australia, TB is a notifiable disease.1 
Notification requirements ensure that 
diseases such as TB can be monitored 
and controlled.12 Incidence has been 
approximated to be 5.7 per 100 000 
population.1 Multi-drug resistant TB 
accounts for approximately 1–2% of 
notifications per year.1 Eighty-six per 
cent of notifications are from Australia’s 
overseas-born population; Aboriginal and 
Torres Strait Islanders have TB rates 6 times 
higher than the Australian-born non-
Indigenous population.1 
The most commonly reported risk 
factor overall (in the Australian-born  
non-Indigenous and overseas-born 
population) was past travel to  
or residence in a high-risk country (see 
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AFTER READING THIS ARTICLE, 
PHARMACISTS SHOULD BE ABLE TO:
• Explain the infectibility of tuberculosis.
• Differentiate between latent tuberculosis 
and active tuberculosis infection.
• Summarise current treatment regimens 
for latent and active tuberculosis 
infections.
• Recognise the common adverse effects, 
precautions and counselling points for 
therapeutic agents used in the treatment 
of tuberculosis.
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country (see Box 1). In the Australian-born 
Indigenous population, the most reported 
risk factor was household or close contact 
with TB.1 In Australia, epidemiological 
evidence of low local transmission and 
TB notification rates suggests that the 
majority of active disease is a result of 
reactivation of latent infection.13 
Latent TB is the persistence of viable 
M. tuberculosis without associated signs 
and symptoms, or active disease.14 It is an 
infection that has been contained but not 
eliminated by the host immune system, 
having the potential to develop into active 
disease, years or decades after initial 
infection (see Figure 1).13 People with 
latent TB are not infectious.15
The current Strategic Plan for Control 
of TB in Australia aims to reduce overall TB 
occurrence to meet pre-elimination targets 
by 2035 in the entire Australian population. 
TB elimination is defined as <1 case per 
million population.11
TB is the most common presenting 
illness in people living with HIV worldwide 
and is the leading cause of mortality. In 
Australia, however, HIV-associated TB 
occurs at low rates and is mainly found 
in the overseas-born population.16 In the 
setting of HIV, clinical manifestation of TB 
depends on degree of immunodeficiency. 
Progression of TB can be more rapid  
and reflective of a subacute rather than 
chronic illness.16 
Multidrug-resistant TB is uncommon in 
Australia, found in approximately 1–3% of 
those diagnosed with TB.9
Diagnosis of TB
A diagnosis of TB should be considered in 
high-risk patient groups and those that 
present with an undiagnosed febrile or 
wasting condition, or a persistent cough 
(symptoms of TB are listed in Box 2).9,17 
Chest X-ray and sputum microscopy 
(acid fast Ziehl-Neelsen stain) form the 
initial investigation for pulmonary TB.9 
Confirmation of diagnosis and drug 
resistance is from sputum culture and 
susceptibility testing.9 
Extrapulmonary TB is diagnosed via 
direct sampling of the likely affected 
organ system.9
References: CDC17
l  Cough that lasts ≥3 weeks
l  Chest pain
l  Haemoptysis
l  Fatigue (or weakness)
l  Anorexia
l Weight loss
l  Fever and chills
l  Night sweats
BOX 2 – SYMPTOMS OF TB
TB = tuberculosis
References: Dept of Health1
l  Past travel to or residence in a
high-risk country
l  Household or close contact with TB
l  Homelessness
l  Residence in a correctional facility
l  Previously untreated TB
l  Current/previous employment in 
healthcare
l  Current immunosuppressive therapy
l  Employment in an institution
l  Residence in an aged care facility
l  Australian-born child with one or more
parent born in a high-risk country








* For patients at high risk of peripheral neuropathy
Reference: eTG9
Ethambutol 15 mg/kg up 
to 1,200 mg daily
Pyrazinamide 25 mg/kg 
up to 2,000 mg
Isoniazid 10 mg/kg up to 
300 mg daily
Rifampicin 10 mg/kg up 
to 600 mg daily
*Pyridoxine 25 mg with








Child <14 years 20 mg/kg up to 1,200 mg 
once daily
Child <14 years 35 mg/kg up to 2,000 mg 
once daily
Isoniazid 10 mg/kg up to 300 mg once daily
Child <14 years (>50 kg) 600 mg once daily
Child <14years (<50 kg) 15 mg/kg up to 450 mg 
once daily





TABLE 1 – Oral treatment regimen for fully drug-susceptible TB
TB = tuberculosis
Risk factors = HIV infection, contact with an infectious person, anti-tumour necrosis factor treatment, dialysis, organ/
haematologic transplantation, silicosis, prison, immigrant from high TB-burden countries, homelessness, illicit drug use
Reference:  WHO14
Exposure Latent TBinfection Active TB
Risk factors
Risk factors
FIGURE 1 – Progression of TB
Prevention and control of TB in 
Australia
Early diagnosis and treatment (including 
treatment of latent TB) is the most eff ective 
way to prevent the transmission of TB.8
Border screening in the form of pre- and 
post-migration screening is undertaken 
by the Department of Immigration and 
Citizenship.8 Vaccination with Bacille 
Calmette-Guerin is only recommended in 
specifi c high risk groups in Australia due 
to its low overall effi  cacy.8 It is, however, 
eff ective in reducing disseminated disease 
and TB meningitis in children under 5 years 
from countries with a high prevalence 
of TB.
In Australia, suspected or confi rmed 
pulmonary TB patients admitted to 
hospital are isolated in negative pressure 
rooms, with droplet precautions, until 
discharge criteria are met (reduction/
absence of cough, reduced smear burden 
or negative smear, assured treatment and 
appropriate discharge plan).8
Treatment of TB
M. tuberculosis is an aerobic, acid fast 
bacilli with low cell wall permeability, 
this confers an intrinsic resistance to 
antibiotics.18,19 Empirical treatment of TB 
involves multidrug regimens to cover any 
pre-existing drug resistance and to prevent 
emerging resistance.⁹
In those with fully drug-susceptible TB, 
there is a 98% initial cure rate and under 
1% 5–year relapse rate when treated with 
pharmacotherapy.9 This involves a four-
drug, 6-month treatment regimen (see 
Table 1).9 Treatment with isoniazid and 
rifampicin is usually for a 6-month period; 
pyrazinamide and ethambutol is indicated 
in the fi rst two months. 
Ethambutol should be continued until 
susceptibility to isoniazid and rifampicin 
can be confi rmed – even if this is beyond 
2 months. However, once susceptibility 
has been confi rmed, ethambutol can be 
ceased before 2 months of therapy has 
been reached. Pyrazinamide should only 
be discontinued after at least 2 months of 
treatment and susceptibility to isoniazid 
and rifampicin have been confi rmed.9
An intermittent, 3–times weekly 
dosing regimen can also be used to treat 
pulmonary TB, however it should only be 
used under the advice of a TB specialist 
and only when the daily TB regimen has 
been used for the fi rst 2 months (further 
information is available in eTG).9
Mechanism of action 
Isoniazid may disrupt the mycobacterial 
cell wall by inhibiting the synthesis of 
mycolic acids. It is both bactericidal 
(against actively dividing M. tuberculosis) 
and bacteriostatic (against resting 
bacteria). It is also a weak monoamine 
oxidase inhibitor (MAOI).20
The rifamycins (rifampicin and 
rifapentine) inhibit RNA polymerase. It is 
bactericidal against rapidly dividing 
M. tuberculosis.21
Complete your 
CPD online at 
psa.org.au/APcpd
55AUSTRALIAN PHARMACIST
Ethambutol may disrupt the cell wall 
by inhibiting the incorporation of mycolic 
acid. It is bacteriostatic against 
M. tuberculosis.22
Pyrazinamide is bacteriacidal against 
M. tuberculosis in acid pH.23
Pyridoxine is a coenzyme in numerous 
reactions and is used to prevent peripheral 
neuropathy in those at high risk of 
developing the condition as a result 
of pharmcotherapy.24
Treatment of latent TB
Completing a course of treatment for 
latent TB can prevent disease progression 
and the possibility of later infection (see 
Figure 1, previous page).14 Treatment 
regimen (see Table 2) is dependent on: 
drug availability, duration of therapy, 
likelihood of drug resistance, potential for 
hepatotoxicity from isoniazid and drug 
interactions with rifamycins. 
Treatment options for TB in the HIV-
infected population are the same as those 
for the general population.16
Treatment for multidrug-resistant TB 
can be found in the WHO consolidated 
guidelines on drug-resistant tuberculosis 
treatment 2019.25
Directly observed therapy
Directly observed therapy (DOT) is 
supervised TB treatment to minimise 
drug resistance and to ensure successful 
treatment completion.3,8 Prior to 
commencement of therapy, patients should 
have an assessment to determine likely 
adherence and evaluate the requirement for 
DOT. In certain situations DOT is mandatory 
(e.g. retreatment or drug resistance).3,8
Conclusion
TB can be fatal if not treated 
appropriately.16 Compliance is important 
for curative intent and prevention of 
resistance.16 Treatment of latent TB 
prevents reactivation and therefore 
later transmission of TB. Pharmacists 
can counsel patients/consumers on 
the nature of TB infections and the 
importance of compliance in addition to 
medicines counselling (see Table 3). The 
curability and preventability of TB and 
the consequences of non-compliance 
should also be emphasised. Resources, 
including multilingual resources can be 
found at the BetterHealth Channel and 
local jurisdictional TB units.8,25
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Epilepsy, CNS toxicity with cycloserine,
risk of peripheral neuropathy 
(malnutrition, diabetes, HIV infection, 
alcoholism)*
Contraindicated in jaundice, may worsen 
hepatic impairment,  risk of hepatotoxicity 
in combination with hepatotoxic drugs 
(e.g. isoniazid),  eff ectiveness of the pill
Use with caution in hepatic impairment. 
Not recommended for use in patients with 
porphyria
Contraindicated in acute gout and 
signifi cant liver disease
Contraindicated in optic neuritis. May cause 
changes in vision. May precipitate gout
None listed
Best absorbed when taken on an empty stomach. 
Tyramine or histamine rich foods can cause 
tachycardia, postural hypotension, fl ushing, itch, 
headache or sweating – avoid if aff ected
Best absorbed when taken at least half an hour before 
food. Take it regularly (allergy is more likely with 
intermittent dosing). Inform prescriber if: rash, fever 
and swollen glands, loss of appetite, nausea, vomiting, 
unusual tiredness, jaundice, dark urine or pale faeces
Best absorbed with meals – high fat meals increase 
absorption
Cease and inform prescriber if: continuous nausea, 
vomiting, unusual tiredness, yellowing of the skin or 
whites of eyes, dark urine or pale faeces
Vision may be aff ected (e.g. clarity and colour). Cease 
and inform prescriber of any changes to eyesight
Avoid unnecessary use. Prolonged high doses may be 
toxic and cause peripheral neuropathy
Nausea, rash, fever, peripheral neuritis,
aminotransferases, hepatitis, acne, fatigue, 
alertness, antinuclear antibodies
GI symptoms (nausea, vomiting, cramps), 
rash,  LFTs, orange-red colouration of body 
fl uids#
Endocrine and metabolic disturbance, 
haematologic reactions, genitourinary 
symptoms, GI, CV, CNS, respiratory and 
ophthalmic symptoms, rash,  LFTs, 
neuromuscular and skeletal symptoms, 





AGENT PRECAUTIONS SELECTED COUNSELLING POINTSCOMMON ADVERSE EFFECTS (>1%)
TABLE 3 – Common adverse eff ects, precautions and counselling points
*use pyridoxine 25mg daily as prophylaxis, #can stain soft contact lenses, UTI=urinary tract infection, GI=gastrointestinal, CV=cardiovascular, CNS=central nervous system
References: MH,20-24 BetterHealth26
*Pyridoxine 25 mg with each dose of isoniazid Duration of 
isoniazid therapy
Child *Pyridoxine 6.25–12.5 mg with each dose of isoniazid
Isoniazid 10 mg/kg up to 300 mg daily
Rifampicin 10 mg/kg up to 600 mg daily
Rifampicin 10 mg/kg up to 600 mg daily
PLUS
Isoniazid 10g/kg up to 300 mg daily
Rifapentine 900 mg weekly
PLUS
Isoniazid 15 mg/kg up to 900 mg weekly
6 months  




Isoniazid 10 mg/kg up to 300 mg once daily
Child <14 years (>50 kg)
rifampicin 600 mg once daily
Child <14 years (<50 kg)
rifampicin 15 mg/kg up to 450 mg 
once daily
Child<14 years (>50 kg)
Rifampicin 600 mg once daily
PLUS
Isoniazid 10g/kg up to 300 mg once 
daily
Child <14 years (<50 mg)
Rifampicin 15 mg/kg up to 450 mg 
once daily
PLUS
Isoniazid 10g/kg up to 300 mg 
once daily
Child ≥12 years (>50 kg)
Rifapentine 900 mg once weekly
Child ≥12 years (32.1–50 kg)
Rifapentine 750 mg once weekly
Child 2–11 years (10–14 kg)
Rifapentine 300 mg once weekly
Child 2–11 years (14.1–25 kg)
Rifapentine 450 mg once weekly
Child 2–11 years (25.1–32 kg)
Rifapentine 600 mg once weekly
Child 2–11 years (32.1–50 kg)
Rifapentine 750 mg once weekly
Child 2–11 years (>50 kg)
Rifapentine 900 mg once weekly
PLUS
Child≥12 years 
Isoniazid 15 mg/kg up to 900 mg 
once weekly
Child 2–11 years





TABLE 2 – Oral treatment regimens for latent TB
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● Tuberculosis is an airborne
pathogen that predominantly 
a ects the lungs.
● It is important to treat both latent 
and active tuberculosis, treatment
guidelines and regimens di er.
● The adverse reactions of 
tuberculosis medicines can
be diverse. 
● Absorption of the medicines used 
in the treatment of tuberculosis can 
be a ected by food, counselling by 
pharmacists is important.
1Which of the following statements aboutthe transmission of tuberculosis is CORRECT?
A)  Mycobacterium tuberculosis is an airborne pathogen that is transmitted by 
inhalation of infectious droplets. Cross infection between humans and 
animals is common. 
B)  Mycobacterium tuberculosis is an airborne pathogen that is transmitted by 
inhalation of infectious droplets and can cause both latent and active 
tuberculosis infections.
C)  Mycobacterium tuberculosis is an airborne pathogen that is transmitted by 
inhalation of infectious droplets that is responsible for zoonotic tuberculosis.
D)   Mycobacterium tuberculosis is an airborne pathogen that is transmitted by 
inhalation of infectious droplets that causes zoonotic tuberculosis from cattle.
2Which of the following statements on the importance oftreating latent tuberculosis is CORRECT?
A)   To prevent the transmission of tuberculosis to other people.
B)   To control symptoms of active tuberculosis.
C)   To prevent progression to active tuberculosis.
D)   To prevent multi-drug resistant tuberculosis.
3Which of the following statements on the standardrecommended treatment regimens for fully drug 
susceptible active tuberculosis is CORRECT?
A)   2 months of ethambutol and pyrazinamide in combination with 6 months of 
isoniazid and rifampicin with or without pyridoxine.
B)   6 months of ethambutol and pyrazinamide in combination with 2 months of 
isoniazid and rifampicin with or without pyridoxine.
C)   6 or 9 months of rifampicin.
D)   4 months of isoniazid with or without pyridoxine.
4Adrian comes into the pharmacy and asks for a lens cleanerfor his soft contact lenses. He has been told by a friend that 
they may help with the pinkish discoloration he has noticed on 
his lenses. During your conversation with Adrian he tells you 
that he is new to wearing contact lenses and has been told by a 
friend that this is not normal. Adrian has recently been 
commenced on a treatment regimen for latent tuberculosis. 
Which of the following statements is CORRECT?
A)   Isoniazid can a ect the colour of bodily  uids which can stain soft contact lenses.
B)   Pyrazinamide can a ect the colour of bodily  uids which can satin soft 
contact lenses.
C)   Rifampicin can a ect the colour of bodily  uids which can stain soft contact lenses.
D)   Ethambutol can a ect the colour of bodily  uids which can stain soft contact lenses.
Assessment questions
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